Roche teas­es 'en­cour­ag­ing' Phase 1 da­ta for weight loss drug from $2.7B Car­mot buy­out

Roche of­fered a glimpse at promis­ing ear­ly ef­fi­ca­cy da­ta on Thurs­day morn­ing from a GLP-1/GIP ag­o­nist it ob­tained as part of its $2.7 bil­lion ac­qui­si­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.